Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 18/20 | 0.76 |
| ▸ | PPARG | P37231 | 7/20 | 0.73 |
| ▸ | PPARD | Q03181 | 8/20 | 0.64 |
| ▸ | PSEN1 | P49768 | 3/20 | 0.62 |
| ▸ | PSEN2 | P49810 | 3/20 | 0.62 |
| ▸ | APH1B | Q8WW43 | 3/20 | 0.62 |
| ▸ | NCSTN | Q92542 | 3/20 | 0.62 |
| ▸ | APH1A | Q96BI3 | 3/20 | 0.62 |
| ▸ | PSENEN | Q9NZ42 | 3/20 | 0.62 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.51 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2086621 | 0.92 | PPARA (0.69) | PPARAPPARGPPARDPSEN1PSEN2 | |
| SCHEMBL2087581 | 0.88 | PPARA (0.62) | PPARAPPARGPPARDPSEN1PSEN2 | |
| SCHEMBL5974323 | 0.88 | PPARA (0.72) | PPARAPPARGPPARDPSEN1PSEN2 | |
| SCHEMBL6497829 | 0.86 | PPARA (1.00) | PPARAPPARGPPARDPSEN1PSEN2 | |
| SCHEMBL2089153 | 0.86 | PPARA (0.69) | PPARAPPARGPPARDPSEN1PSEN2 | |
| SCHEMBL5974097 | 0.84 | PPARA (0.80) | PPARAPPARGPPARDPSEN1PSEN2 | |
| SCHEMBL13002353 | 0.80 | PPARA (0.53) | PPARAPPARGPPARDDUSP3 | |
| SCHEMBL5974498 | 0.80 | PPARA (0.72) | PPARAPPARGPPARDPSEN1PSEN2 | |
| SCHEMBL5093339 | 0.80 | PPARA (0.56) | PPARAPPARGPPARDPSEN1PSEN2 | |
| SCHEMBL6380273 | 0.80 | PPARA (0.84) | PPARAPPARGPPARDPSEN1PSEN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8604083-B2 | Method for the treatment of metabolic disorders | WELLSTAT THERAPEUTICS CORPORATION (US) | 2013-12-10 | — | — | US | claimed |
| US-20070244172-A1 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | WELLSTAT THERAPEUTICS CORPORATION (US) | 2007-10-18 | — | — | US | claimed |
| US-6946491-B2 | Compounds for the treatment of metabolic disorders | WELLSTAT THERAPEUTICS CORPORATION (US) | 2005-09-20 | — | — | US | claimed |
| US-20040092516-A1 | Compounds for the treatment of metabolic disorders | PHARMA CINQ, LLC | 2004-05-13 | — | — | US | claimed |
| US-9133073-B2 | Compounds for the treatment of metabolic disorders | WELLSTAT THERAPEUTICS CORPORATION (US) | 2015-09-15 | — | — | US | disclosed |
| US-8604083-B2 | Method for the treatment of metabolic disorders | WELLSTAT THERAPEUTICS CORPORATION (US) | 2013-12-10 | — | — | US | disclosed |
| US-20130281705-A1 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | WELLSTAT THERAPEUTICS CORP (US) | 2013-10-24 | — | — | US | disclosed |
| US-8552062-B2 | Methods for the treatment of metabolic disorders such as diabetes | WELLSTAT THERAPEUTICS CORPORATION (US) | 2013-10-08 | — | — | US | disclosed |
| US-8487000-B2 | 4-(3-(2,6-Dimethoxybenzyloxy)phenyl)-4-oxobutyric acid or derivatives for treatment of insulin resistance syndrome, diabetes, cachexia, hyperlipidemia, fatty liver disease, obesity, atherosclerosis or arteriosclerosis | Wellstat Therapertics Corporation (US) | 2013-07-16 | — | — | US | disclosed |
| US-7932290-B2 | Method for the treatment of metabolic disorders | WELLSTAT BIOLOGICS CORPORATION (US) | 2011-04-26 | — | — | US | disclosed |
| US-7863475-B2 | Compounds for the treatment of metabolic disorders | WELLSTAT THERAPEUTICS CORPORATION (US) | 2011-01-04 | — | — | US | disclosed |
| EP-2266946-A2 | Compound For The Treatment Of Metabolic Disorders | Wellstat Therapeutics Corporation (US) | 2010-12-29 | — | — | EP | disclosed |
| US-20040267025-A1 | Compounds for the treatment of metabolic disorders | WELLSTAT THERAPEUTICS CORPORATION | 2004-12-30 | — | — | US | disclosed |
| US-20040242692-A1 | Compounds for the treatment of metabolic disorders | WELLSTAT THERAPEUTICS CORPORATION | 2004-12-02 | — | — | US | disclosed |
| US-20040236100-A1 | Compounds for the treatment of metabolic disorders | WELLSTAT THERAPEUTICS CORPORATION | 2004-11-25 | — | — | US | disclosed |
| WO-2004073611-A2 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | WELLSTAT THERAPEUTICS CORPORATION (US) | 2004-09-02 | — | — | WO | disclosed |
| US-20040097585-A1 | Compounds for the treatment of metabolic disorders | WELLSTAT THERAPEUTICS CORPORATION | 2004-05-20 | — | — | US | disclosed |
| US-20040092516-A1 | Compounds for the treatment of metabolic disorders | PHARMA CINQ, LLC | 2004-05-13 | — | — | US | disclosed |
| US-20040092518-A1 | Compounds for the treatment of metabolic disorders | PHARMA CINQ, LLC | 2004-05-13 | — | — | US | disclosed |
| US-20040077896-A1 | Compounds for the treatment of metabolic disorders | WELLSTAT THERAPEUTICS CORPORATION | 2004-04-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040267025-A1 | Compounds for the treatment of metabolic disorders | GOT2, OAT, CPT1B | PPARA 139/4885PPARG 81/4885PPARD 205/4885 |
| US-20040092516-A1 | Compounds for the treatment of metabolic disorders | GOT2, OAT, CPT1B | PPARA 139/4885PPARG 81/4885PPARD 205/4885 |
| US-20040092518-A1 | Compounds for the treatment of metabolic disorders | GOT2, OAT, CPT1B | PPARA 139/4885PPARG 81/4885PPARD 205/4885 |
| US-20130281705-A1 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | GOT2, OAT, CPT1B | PPARA 139/4885PPARG 81/4885PPARD 205/4885 |
| US-20040097585-A1 | Compounds for the treatment of metabolic disorders | GOT2, OAT, CPT1B | PPARA 139/4885PPARG 81/4885PPARD 205/4885 |
| US-20040242692-A1 | Compounds for the treatment of metabolic disorders | GOT2, OAT, CPT1B | PPARA 139/4885PPARG 81/4885PPARD 205/4885 |
| US-20040077896-A1 | Compounds for the treatment of metabolic disorders | GOT2, OAT, CPT1B | PPARA 139/4885PPARG 81/4885PPARD 205/4885 |
| US-20040236100-A1 | Compounds for the treatment of metabolic disorders | GOT2, OAT, CPT1B | PPARA 139/4885PPARG 81/4885PPARD 205/4885 |
| US-20070244172-A1 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | GOT2, OAT, CPT1B | PPARA 139/4885PPARG 81/4885PPARD 205/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.